Sugi Predict

Sugi Predict / Compounds / SCHEMBL1472410

SCHEMBL1472410

SCHEMBL1472410

C=CCCC(=O)NCCC(=O)O

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ECE1 P42892 1/20 0.50
▸ MAPT P10636 3/20 0.47
▸ ABCC4 O15439 1/20 0.47
▸ FAAH O00519 3/20 0.46
▸ CNR1 P21554 3/20 0.46
▸ CNR2 P34972 2/20 0.46
▸ TSHR P16473 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ EPHX2 P34913 2/20 0.40
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ SLC6A5 Q9Y345 1/20 0.38
▸ ITGB3 P05106 2/20 0.37
▸ ITGA2B P08514 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ ALDH1A1 P00352 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10005868 0.88 MAPT (0.53) MAPTABCC4FAAHCNR1CNR2
SCHEMBL13938722 0.87 MAPT (0.48) MAPTABCC4FAAHCNR1TSHR
SCHEMBL10005869 0.86 MAPT (0.57) MAPTABCC4FAAHCNR1CNR2
SCHEMBL10040321 0.85 ABCC4 (0.60) MAPTABCC4FAAHCNR1CNR2
SCHEMBL22856074 0.85 MAPT (0.46) MAPTABCC4FAAHCNR1TSHR
SCHEMBL3176010 0.83 MAPT (0.47) ECE1MAPTABCC4FAAHCNR1
SCHEMBL14586442 0.82 MAPT (0.41) MAPTABCC4FAAHCNR1CNR2
SCHEMBL3794429 0.81 FAAH (0.53) MAPTABCC4FAAHTSHRSMN1; SMN2
SCHEMBL13528442 0.81 CNR1 (0.53) MAPTFAAHCNR1CNR2TSHR
SCHEMBL9717431 0.79 ECE1 (0.65) ECE1FAAHCNR1CNR2ITGB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240166689-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-05-23 — — US disclosed
US-11891457-B2 Peptide-compound cyclization method CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-02-06 — — US disclosed
EP-2813512-B1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI PHARMACEUTICAL CO LTD (JP) 2021-03-31 — — EP disclosed
US-20210061860-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2021-03-04 — — US disclosed
US-20160311858-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-10-27 — — US disclosed
US-9409952-B2 Peptide-compound cyclization method CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-08-09 — — US disclosed
US-9096951-B2 Method for producing second-generation library NUEVOLUTION A/S (DK) 2015-08-04 — — US disclosed
US-9096951-B2 Method for producing second-generation library NUEVOLUTION A/S (DK) 2015-08-04 — — US disclosed
US-20150080549-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-03-19 — — US disclosed
EP-2813512-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD Chugai Seiyaku Kabushiki Kaisha (JP) 2014-12-17 — — EP disclosed
US-20120028812-A1 METHOD FOR PRODUCING SECOND-GENERATION LIBRARY NUEVOLUTION A/S (DK) 2012-02-02 — — US disclosed
US-20120028812-A1 METHOD FOR PRODUCING SECOND-GENERATION LIBRARY NUEVOLUTION A/S (DK) 2012-02-02 — — US disclosed
US-7915201-B2 Ligational encoding of small molecules NUEVOLUTION A/S (DK) 2011-03-29 — — US disclosed
EP-2236606-A2 Ligational encoding of small molecules Nuevolution A/S (DK) 2010-10-06 — — EP disclosed
US-20090239211-A1 Method For Enrichment Involving Elimination By Mismatch Hybridisation NUEVOLUTION A/S (DK) 2009-09-24 — — US disclosed
US-20090239211-A1 Method For Enrichment Involving Elimination By Mismatch Hybridisation NUEVOLUTION A/S (DK) 2009-09-24 — — US disclosed
EP-1608748-B1 LIGATIONAL ENCODING OF SMALL MOLECULES NUEVOLUTION AS (DK) 2009-03-04 — — EP disclosed
US-20060246450-A1 Ligational encoding of small molecules NUEVOLUTION A/S (DK) 2006-11-02 — — US disclosed
EP-1608748-A2 LIGATIONAL ENCODING OF SMALL MOLECULES Nuevolution A/S (DK) 2005-12-28 — — EP disclosed
WO-2004083427-A2 LIGATIONAL ENCODING OF SMALL MOLECULES NUEVOLUTION A/S (DK) 2004-09-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11891457-B2 Peptide-compound cyclization method VIP, NGLY1, GLP1R ECE1 1188/4885MAPT 3614/4885ABCC4 2371/4885
US-20210061860-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD VIP, NGLY1, GLP1R ECE1 1188/4885MAPT 3614/4885ABCC4 2371/4885
US-20060246450-A1 Ligational encoding of small molecules POLI, PCNA, LIG4 ECE1 3366/4885MAPT 3633/4885ABCC4 2580/4885
US-20240166689-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD VIP, NGLY1, GLP1R ECE1 1188/4885MAPT 3614/4885ABCC4 2371/4885
US-20160311858-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD VIP, NGLY1, GLP1R ECE1 1188/4885MAPT 3614/4885ABCC4 2371/4885
US-20150080549-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD VIP, NGLY1, GLP1R ECE1 1188/4885MAPT 3614/4885ABCC4 2371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.